Clinical Trial

Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 3, 2025 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this single arm, prospective study is to test the therapeutic response of oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks in non-diabetic MAFLD patients. The primary outcomes are the improvement of liver inflammation or fibrosis parameters after 24 weeks treatment. The adverse events were also recorded.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-03-13; most recent amendment 2025-02-27.
Status change: Recruiting → Active, Not Recruiting 2025-02-27
Status change: Not Yet Recruiting → Recruiting 2023-08-06
Trial Details
NCT Number NCT05782972
Lead Sponsor Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Conditions Metabolic Associated Fatty Liver Disease
Enrollment 50 participants
Start Date 2023-03-11
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-03